comparemela.com

Latest Breaking News On - Ziftomenib - Page 1 : comparemela.com

FDA Grants Breakthrough Therapy Designation to Ziftomenib in NPM1-Mutant AML

The FDA has granted breakthrough therapy designation to ziftomenib for the treatment of NPM1-mutant acute myeloid leukemia.

Germany
Troy-wilson
Kura-oncology
Ziftomenib
Npm1-mutant-acute-myeloid-leukemia

Ziftomenib Combos Show Early Safety, Activity in NPM1-Mutant and KMT2A-Rearranged AML

An acceptable safety profile and early evidence of clinical activity was observed with ziftomenib plus standard regimens in select patients with AML.

Samer-zeidan
Division-of-hematologic-malignancies
Hematologic-malignancies
Hematology-early-therapeutics-research
Yale-cancer-center
Ziftomenib
Phase-1-2-komet-007-trial-
Nct04067336
Aml
Acute-myeloid-leukemia
Npm1-mutant-and-kmt2a-rearranged-
Npm1-mutant-and-kmt2a-rearranged-aml

Kura Gains 17% Over Positive Preliminary Clinical Data From Phase 1 Trial Of Ziftomenib

Stock of Kura Oncology, Inc. (KURA) gained 15 percent on Tuesday morning after the company announced positive preliminary clinical data from phase 1 trial Of Ziftomenib.

United-kingdom
British
England-prudential-regulation-authority
General-motors-co
New-york-stock-exchange
Drug-administration
York-stock-exchange
Neptune-resources
Holdings-plc
General-motors
New-york-stock

Activity, Tolerability and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed or Refractory NPM1-Mutated AML

Expert Amir Fathi, MD, reviews recent clinical data with ziftomenib in patients with relapsed/refractory acute myeloid leukemia.

Amir-fathi
Resistance-profile
Menin-inhibitor-ziftomenib
Adults-with
Aml
Acute-myeloid-leukemia
Npm1
Npm1-mutations
Relapsed-refractory-aml
Ziftomenib
Novel-therapy

Dr Fathi on Ziftomenib in R/R NPM1-Mutant AML

Amir Fathi, MD, discusses findings from the phase 1b expansion portion of the phase 1/2 KOMET-001 trial in patients with relapsed/refractory acute myeloid leukemia harboring NPM1 mutations.

Massachusetts
United-states
Amir-fathi
Harvard-medical-school
Massachusetts-general-hospital
D
Komet-001-trial
Patients-with-relapsed-refractory-acute-myeloid-leukemia-harboring-npm1-mutations
Ziftomenib
Nct04067336

vimarsana © 2020. All Rights Reserved.